Trial Profile
A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol in the treatment of bronchiectasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Mannitol (Primary)
- Indications Bronchiectasis
- Focus Registrational; Therapeutic Use
- Sponsors Pharmaxis; Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 09 Sep 2013 Primary endpoint 'Symptom-exacerbation-rate' has not been met.